Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
- Author:
Rishil J KATHAWALA
1
;
Yi-Jun WANG
;
Charles R ASHBY
;
Zhe-Sheng CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; Benzamides; Benzylisoquinolines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Imidazoles; Multidrug Resistance-Associated Proteins; antagonists & inhibitors; Piperazines; Purines; Pyrimidines; Quinazolines; Sildenafil Citrate; Sulfonamides; Sulfones; Taxoids; Triazines; Vardenafil Dihydrochloride
- From:Chinese Journal of Cancer 2014;33(5):223-230
- CountryChina
- Language:English
- Abstract: ABCC10, also known as multidrug-resistant protein 7 (MRP7), is the tenth member of the C subfamily of the ATP-binding cassette (ABC) superfamily. ABCC10 mediates multidrug resistance (MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs. The ABCC10 transporter is a 171-kDa protein that is localized on the basolateral cell membrane. ABCC10 is a broad-specificity transporter of xenobiotics, including antitumor drugs, such as taxanes, epothilone B, vinca alkaloids, and cytarabine, as well as modulators of the estrogen pathway, such as tamoxifen. In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR. This review discusses some recent and clinically relevant aspects of the ABCC10 drug efflux transporter from the perspective of current chemotherapy, particularly its inhibition by tyrosine kinase inhibitors and phosphodiesterase type 5 inhibitors.
